ByteDance has spun off its AI drug discovery unit into an independent company that just raised $290 million at a $1.5 billion valuation, marking a significant shift in how tech giants are diversifying into biotech. The newly independent Anew Labs closed the funding round with backing from HSG (formerly known as Sequoia China), IDG Capital, and Hillhouse Investment, among others, while ByteDance retained a 56% stake in the business.

This move represents more than just a capital raise. It signals a broader trend where technology companies with advanced artificial intelligence capabilities are applying those tools to solve problems in drug discovery and development, an industry traditionally dominated by pharmaceutical companies and specialized biotech firms. ByteDance's decision to spin out Anew Labs as an independent entity suggests the company believes AI-driven drug discovery operates under fundamentally different business logic and management principles than its core social media and software businesses.

What Makes Anew Labs' Technology Noteworthy?

Anew Labs has already developed several proprietary AI models and drug candidates that demonstrate the potential of this approach. The company has created structure-prediction and protein-design models called Protenix and PXDesign, which represent the cutting edge of AI-assisted molecular biology. More concretely, the team has four drug candidates in development, including an AI-designed IL-17 inhibitor that was showcased at the American Association of Immunologists' meeting in Boston in April.

The company's technical achievements underscore why major investors are willing to back a drug discovery startup with no approved medicines yet. In the pharmaceutical industry, the ability to computationally design promising drug candidates can dramatically accelerate the early stages of development, potentially saving years of laboratory work. Anew Labs' team of approximately 50 core staff members brings both AI expertise and domain knowledge in biology, with operations spanning Shanghai, Singapore, and San Jose, California.

How Does Anew Labs Plan to Scale Its Operations?

• Computing Infrastructure: Volcano Engine, ByteDance's cloud computing division, will continue providing the computational power necessary to train and run AI models for drug discovery, eliminating the need for Anew Labs to build its own data center infrastructure.
• Leadership and Expertise: The company is headed by Liu Kai, who spent seven years in venture capital at IDG Capital and Fire Stone Investment before joining ByteDance in 2021, bringing both operational and fundraising experience to the role.
• Geographic Expansion: With offices in three major biotech and tech hubs, Anew Labs can access talent pools in Asia and North America while maintaining proximity to regulatory agencies and research institutions in each region.

The funding round itself reflects confidence from some of Asia's most prominent venture capital firms. Beyond HSG and IDG Capital, the round included participation from 5Y Capital as a co-lead, along with Gaorong Ventures, Primavera Venture Partners, Boyu Capital, and the state-supported Shanghai Future Industries Fund. SBP Group joined as a strategic investor.

Why Are Tech Companies Entering Drug Discovery?

For ByteDance, which owns TikTok and CapCut, adding a drug development company to its portfolio might seem unusual at first glance. However, the move reflects a strategic recognition that artificial intelligence excels at pattern recognition and molecular design tasks that are foundational to early-stage drug discovery. By spinning out Anew Labs, ByteDance is positioning itself to capture value from its AI capabilities in a high-stakes industry where successful drug candidates can generate billions in revenue.

The spinoff was described by industry observers as ByteDance's first major step toward commercializing its broader AI-for-science efforts. Rather than keeping the drug discovery work as an internal research project, the company chose to create an independent entity with its own governance, investor base, and commercial incentives. This structure allows Anew Labs to pursue partnerships, licensing deals, and eventual public markets opportunities without being constrained by ByteDance's social media and entertainment business priorities.

The $1.5 billion valuation reflects investor expectations that AI-driven drug discovery can compress timelines and reduce costs in an industry where bringing a single drug to market typically costs over $2 billion and takes more than a decade. If Anew Labs can demonstrate that its AI models accelerate the path from candidate identification to clinical trials, the company could become a valuable asset in its own right, independent of ByteDance's ownership stake.